However, in low- and middle-income countries (LMIC) where molecular studies are yet not available, immunohistochemical stains (H3K27M, H3K27me3, H3G34R/V, IDH-1, R132H, ATRX, p53 olig-two and BRAF V600E) can be used in classifying high grade glioma according to the recent WHO classification for clinical management purpose. This evidence concerns the gene IDH1 and central nervous system cancer.